Key result
Bone marrow-derived cell transfer offers potential cardiac function improvements after myocardial infarction.
Answers are grounded in this paper and cite their sources.
Despite substantial advances in treatment, ischemic cardiac injury and the ventricular dysfunction it can provoke remain major causes of morbidity and mortality throughout the world. The endogenous regenerative capacity of the heart appears inadequate to repair injured myocardium, leading to the cumulative loss of cardiomyocytes over the lifetime of a patient. This may contribute to the prevalence of heart failure as a diagnosis at hospital admission — particularly among the elderly.For these reasons, experiments in animals suggesting that the transfer of cells derived from bone marrow (BMC) could dramatically improve cardiac function after infarction through regeneration of the myocardium . . .
No takes yet. Share an insight, caveat, or question.
Anthony Rosenzweig (2006) conducted an editorial in Ischemic cardiac injury and ventricular dysfunction. Bone marrow-derived cell (BMC) therapy was evaluated. Bone marrow-derived cell transfer is discussed for improving cardiac function after myocardial infarction, though no quantitative trial results are reported in this excerpt.
Synapse has enriched 10 related papers. Consider them for comparative context: